Trial reportPituitary2015
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Trial report in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis.Journal of endocrinological investigation · 2018Pooled it
- Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment:Frontiers in endocrinology · 2024Trial
- The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.Journal of endocrinological investigation · 2020Trial
- Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.Clinical endocrinology · 2019Trial
- Trial
- Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.Journal of endocrinological investigation · 2018Trial
- Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.Endocrine · 2017Trial
- The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.Endocrine · 2015Trial
- Efficacy and safety of pasireotide in patients with Cushing's disease: a monocentric experience.Endocrine · 2025Article
- Real-World Experience with Pasireotide-LAR in Cushing's Disease: Single-Center 12-Month Observational Study.Journal of clinical medicine · 2025Article
- Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).Pituitary · 2025Article
- Current and Emerging Pharmacological Therapies for Cushing's Disease.Current pharmaceutical design · 2024Review
- Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line.Journal of endocrinological investigation · 2023Article
- An individualized approach to the management of Cushing disease.Nature reviews. Endocrinology · 2023Review
- Unmet needs on the current medical management of Cushing's syndrome: results from a Delphi panel of Italian endocrinologists.Journal of endocrinological investigation · 2023Article
- Pasireotide-a novel somatostatin receptor ligand after 20 years of use.Reviews in endocrine & metabolic disorders · 2022Review
- Pasireotide treatment in Cushing's disease: A single tertiary center's experience.Turkish journal of medical sciences · 2022Article
- Current and Emerging Medical Therapies in Pituitary Tumors.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeReport the efficacy and safety of pasireotide sc in patients with Cushing's disease during an open-ended, open-label extension to a randomized, double-blind, 12-month, Phase III study.
methods162 patients entered the core study. 58 patients who had mean UFC ≤ ULN at month 12 or were benefiting clinically from pasireotide entered the extension. Patients received the same dose of pasireotide as at the end of the core study (300-1,200 μg bid). Dose titration was permitted according to efficacy or drug-related adverse events.
results40 patients completed 24 months' treatment. Of the patients who entered the extension, 50.0% (29/58) and 34.5% (20/58) had controlled UFC (UFC ≤ ULN) at months 12 and 24, respectively. The mean percentage decrease in UFC was 57.3% (95% CI 40.7-73.9; n = 52) and 62.1% (50.8-73.5; n = 33) after 12 and 24 months' treatment, respectively. Improvements in clinical signs of Cushing's disease were sustained up to month 24. The most frequent drug-related adverse events in patients who received ≥1 dose of pasireotide (n = 162) from core baseline until the 24-month cut-off were diarrhea (55.6%), nausea (48.1%), hyperglycemia (38.9%), and cholelithiasis (31.5%). No new safety issues were identified during the extension.
conclusionsReductions in mean UFC and improvements in clinical signs of Cushing's disease were maintained over 24 months of pasireotide treatment. The safety profile of pasireotide is typical for a somatostatin analogue, except for the frequency and degree of hyperglycemia; patients should be monitored for changes in glucose homeostasis. Pasireotide represents the first approved pituitary-targeted treatment for patients with Cushing's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.